Drug maker Lupin today announced the launch of its Olmesartan Medoxomil tablets, a hypertension drug, in the US market.
The company has launched the tablets in strengths of 5 mg, 20 mg and 40 mg after having received an approval from the United States Food and Drug Administration (FDA) earlier, Lupin Ltd said in a statement.
The Mumbai-based company's product is the generic equivalent of Daiichi Sankyo Inc's Benicar tablets which is indicated for the treatment of hypertension.
As per IMS MAT data for July 2017, Benicar tablets had US sales of USD 681 million.
Lupin shares were trading 0.15 per cent down at Rs 992 on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)